U.S. drug demand recovering with economy; Nexavar delays breast cancer in new study;

@FiercePharma: Generics, emerging markets to take over pharma growth. Story | Follow @FiercePharma

> There's new evidence that the drop in patient demand for medications during the recession is starting to reverse. Report

> Nexavar, the cancer drug sold by Onyx Pharmaceuticals and Bayer was shown to delay tumor progression in women with advanced breast cancer, according to a new study. Story

> Silenor, the new sleeping pill made by Somaxon Pharmaceuticals, is under the threat of competition from yet another generic drug maker. News

> Adverse event data show the risks of serious psychiatric side effects of Chantix, the smoking-cessation drug, were previously underestimated because Pfizer apparently failed to correctly submit hundreds of episodes to the FDA, the Institute for Safe Medicine Practices says. Article

> Shire Pharmaceuticals received an FDA warning letter stating that the company's promotional magnets advertising the attention deficit disorder drug Vyvanse are misleading. Piece

> A federal advisory panel unanimously recommended that dosing for children's acetaminophen be based primarily on the child's weight rather than age. Item

> Prostate cancer screening beginning from ages 44 to 50 may rule out the risk of dying in half of men, according to a study that showed some men may need as few as three screening tests in a lifetime. Report

Biotech News

@FierceBiotech: Canaan cashing in on Shire's $750M deal for Advanced BioHealing. Item | Follow @FierceBiotech

@JohnCFierce: Another interesting point: "More than 90 percent of recently approved cancer drugs cost more than $20,000 for a 12-week course of therapy. Follow @JohnCFierce

> Takeda wraps $13.7B Nycomed buyout, skin unit spins off. News

> Abiraterone vs. MDV3100: A prostate cancer drug showdown. Article 

> Proteomics companies create new network. News 

> Gallus Bio blueprints expansion, new hires at biologics plant. Report 

> ASCO abstracts flag new data on the hottest cancer drugs. Item

> "ASCO effect" drives up shares of troubled OXiGENE. Article 

Vaccines News

> Chongqing bids $93M for Bilthoven. Story 

> Cancer vaccine market to hit $7B by 2015. Report

> Study: HPV vax important for men. Item 

> Sanofi plots 2014 launch of new dengue vaccine. Story

> Celiac disease vax has positive Ph1 results. Article

Manufacturing News

> Golden State warning cites repeat violation. Article

> Particle detection pits man against machine. News

> Packager Amcor hears dual sustainability calls. Story 

> Pfizer's Viagra faces more counterfeit, generic attacks. News

> How GSK rose from a lonely, inventive shepherd. Report

And Finally... Stimulant medications to treat attention-deficit hyperactivity disorder are popular pills on college campuses during finals week. Story

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.